• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当前外周动脉疾病的管理:聚焦于药物治疗。

Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy.

机构信息

Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia.

The Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, QLD, Australia.

出版信息

Drugs. 2022 Jul;82(11):1165-1177. doi: 10.1007/s40265-022-01755-7. Epub 2022 Aug 12.

DOI:10.1007/s40265-022-01755-7
PMID:35960432
Abstract

Peripheral artery disease (PAD) is the occlusion or narrowing of the arteries supplying the lower extremities. Peripheral artery disease has been estimated to affect approximately 240 million people worldwide, approximately 70% of whom are within low- or middle-income countries. Due to the ageing population and diabetes epidemic, the prevalence of PAD is rapidly rising. The symptoms of PAD are heterogeneous and thus a high index of suspicion is needed to prevent delays in diagnosis and treatment. Measurement of ankle brachial pressure index or arterial duplex ultrasound are traditionally used to diagnose PAD. Patients with PAD have a high risk of major adverse cardiovascular events. Early diagnosis and implementation of secondary cardiovascular prevention is therefore critical. This includes therapies to reduce low-density lipoprotein cholesterol, such as statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, blood-pressure reducing medications and anti-thrombotic drugs. Treatments to facilitate smoking cessation and control blood sugar if relevant and an exercise programme are also critical in reducing cardiovascular risk. Currently, these treatments are not well implemented. This review summarises the clinical presentation, risk factors and medical management of PAD. Global efforts are needed to reduce the burden from the growing PAD epidemic by implementing best practices and improving outcomes through further research.

摘要

外周动脉疾病(PAD)是指供应下肢的动脉阻塞或变窄。据估计,全球约有 2.4 亿人患有外周动脉疾病,其中约 70%的人生活在中低收入国家。由于人口老龄化和糖尿病流行,PAD 的患病率正在迅速上升。PAD 的症状多种多样,因此需要高度怀疑才能防止诊断和治疗的延误。传统上使用踝肱血压指数或动脉双功能超声来诊断 PAD。PAD 患者发生主要不良心血管事件的风险很高。因此,早期诊断和实施二级心血管预防至关重要。这包括降低低密度脂蛋白胆固醇的治疗方法,如他汀类药物、依折麦布和前蛋白转化酶枯草溶菌素 9(PCSK9)抑制剂、降低血压的药物和抗血栓药物。如果相关,还需要促进戒烟和控制血糖的治疗以及运动方案,以降低心血管风险。目前,这些治疗方法并没有得到很好的实施。这篇综述总结了 PAD 的临床表现、危险因素和医学管理。需要全球共同努力,通过实施最佳实践和通过进一步研究改善结果来减轻日益严重的 PAD 流行带来的负担。

相似文献

1
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy.当前外周动脉疾病的管理:聚焦于药物治疗。
Drugs. 2022 Jul;82(11):1165-1177. doi: 10.1007/s40265-022-01755-7. Epub 2022 Aug 12.
2
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).依洛尤单抗降低低密度脂蛋白胆固醇水平及外周动脉疾病患者的结局:来自 FOURIER 试验(在高风险人群中用 PCSK9 抑制剂进行进一步心血管结局研究)的见解。
Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13.
3
Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.下肢外周动脉疾病的支架置入术:一项基于证据的分析。
Ont Health Technol Assess Ser. 2010;10(18):1-88. Epub 2010 Sep 1.
4
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.急性冠状动脉综合征后外周动脉疾病和静脉血栓栓塞事件:脂蛋白(a)的作用和依洛尤单抗的修饰:ODYSSEY OUTCOMES 随机临床试验的预设分析。
Circulation. 2020 May 19;141(20):1608-1617. doi: 10.1161/CIRCULATIONAHA.120.046524. Epub 2020 Mar 29.
5
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南:基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
6
Lipid-lowering therapies in peripheral artery disease: A review.外周动脉疾病的降脂治疗:综述。
Vasc Med. 2021 Feb;26(1):71-80. doi: 10.1177/1358863X20957091. Epub 2020 Oct 19.
7
Lipid-lowering treatment in peripheral artery disease.外周动脉疾病的降脂治疗。
Curr Opin Pharmacol. 2018 Apr;39:19-26. doi: 10.1016/j.coph.2018.01.003. Epub 2018 Feb 4.
8
Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.外周动脉疾病患者血浆中前蛋白转化酶枯草杆菌蛋白酶/克新蛋白酶9型水平升高,且与代谢紊乱及循环祖细胞功能障碍相关。
J Am Heart Assoc. 2016 May 20;5(5):e003497. doi: 10.1161/JAHA.116.003497.
9
Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study.血清 PCSK9 水平升高与男性有症状外周动脉疾病的关系:CAVASIC 研究。
Atherosclerosis. 2021 Jan;316:41-47. doi: 10.1016/j.atherosclerosis.2020.11.025. Epub 2020 Nov 28.
10
PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.抑制前蛋白转化酶枯草溶菌素9以降低低密度脂蛋白及其他作用——对周围动脉疾病患者的影响
Vasa. 2018 Apr;47(3):165-176. doi: 10.1024/0301-1526/a000689. Epub 2018 Feb 7.

引用本文的文献

1
Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic peripheral arterial disease.症状性外周动脉疾病患者血管介入成功后额外运动疗法的效果
Cochrane Database Syst Rev. 2024 May 2;5(5):CD014736. doi: 10.1002/14651858.CD014736.pub2.
2
Translational Relevance of Advanced Age and Atherosclerosis in Preclinical Trials of Biotherapies for Peripheral Artery Disease.外周动脉疾病生物疗法临床前试验中高龄与动脉粥样硬化的转化相关性
Genes (Basel). 2024 Jan 22;15(1):135. doi: 10.3390/genes15010135.
3
Dyslipidemia and peripheral arterial disease.

本文引用的文献

1
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.总心血管和肢体事件以及慢性有症状外周动脉疾病中多血管疾病的影响。
J Am Heart Assoc. 2022 Jun 7;11(11):e025504. doi: 10.1161/JAHA.122.025504. Epub 2022 May 27.
2
Polyvascular disease, pulse pressure and mortality.多发性血管疾病、脉压与死亡率。
Vasa. 2022 Jul;51(4):229-238. doi: 10.1024/0301-1526/a001011. Epub 2022 May 23.
3
Update on the pathophysiology and medical treatment of peripheral artery disease.
血脂异常与外周动脉疾病。
Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S86-S89. doi: 10.1016/j.ihj.2024.01.010. Epub 2024 Jan 13.
4
Hypertension Management in Peripheral Artery Disease: A Mini Review.外周动脉疾病的高血压管理:小型综述。
Curr Hypertens Rev. 2024;20(1):1-9. doi: 10.2174/0115734021267004231122061712.
5
Circulating Amino Acids and Risk of Peripheral Artery Disease in the PREDIMED Trial.循环氨基酸与 PREDIMED 试验中外周动脉疾病的风险。
Int J Mol Sci. 2022 Dec 23;24(1):270. doi: 10.3390/ijms24010270.
外周动脉疾病的病理生理学和医学治疗进展。
Nat Rev Cardiol. 2022 Jul;19(7):456-474. doi: 10.1038/s41569-021-00663-9. Epub 2022 Jan 7.
4
Cohort Study Examining the Prevalence and Relationship with Outcome of Standard Modifiable Risk Factors in Patients with Peripheral Artery Occlusive and Aneurysmal Disease.队列研究探讨外周动脉阻塞和动脉瘤疾病患者标准可改变风险因素的患病率及与结局的关系。
Eur J Vasc Endovasc Surg. 2022 Feb;63(2):305-313. doi: 10.1016/j.ejvs.2021.10.039. Epub 2021 Dec 13.
5
A meta-analysis of randomized controlled trials evaluating the efficacy of smoking cessation interventions in people with peripheral artery disease.一项荟萃分析随机对照试验评估戒烟干预在周围动脉疾病患者中的疗效。
J Vasc Surg. 2022 Feb;75(2):721-729.e7. doi: 10.1016/j.jvs.2021.07.248. Epub 2021 Sep 30.
6
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.外周动脉疾病患者使用低剂量利伐沙班和阿司匹林:COMPASS和VOYAGER试验的荟萃分析
Eur J Prev Cardiol. 2022 May 5;29(5):e181-e189. doi: 10.1093/eurjpc/zwab128.
7
Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association.下肢外周动脉疾病:当代流行病学、管理差距与未来方向:美国心脏协会科学声明。
Circulation. 2021 Aug 31;144(9):e171-e191. doi: 10.1161/CIR.0000000000001005. Epub 2021 Jul 28.
8
Cilostazol for intermittent claudication.西洛他唑治疗间歇性跛行。
Cochrane Database Syst Rev. 2021 Jun 30;6(6):CD003748. doi: 10.1002/14651858.CD003748.pub5.
9
Long Term Survival and Limb Salvage in Patients With Non-Revascularisable Chronic Limb Threatening Ischaemia.无法血运重建的慢性肢体威胁性缺血患者的长期生存和保肢。
Eur J Vasc Endovasc Surg. 2021 Aug;62(2):225-232. doi: 10.1016/j.ejvs.2021.04.003. Epub 2021 Jun 2.
10
Associations of Clinical Frailty with Severity of Limb Threat and Outcomes in Chronic Limb-threatening Ischaemia.临床虚弱与肢体威胁严重程度及慢性肢体威胁性缺血结局的关联。
Ann Vasc Surg. 2021 Oct;76:406-416. doi: 10.1016/j.avsg.2021.04.017. Epub 2021 May 2.